Merck's ADC Sac-TMT Gets Its First Global Phase 3 Win Ahead of Schedule

Why It Matters

The breakthrough provides Merck a new revenue stream to offset anticipated losses from Keytruda’s patent expiry and showcases the commercial potential of ADC collaborations with Chinese biotech firms.

Key Takeaways

• sac‑TMT met primary endpoint in global Phase 3 trial.
• Trial showed 30% reduction in progression‑free survival risk.
• Enrollment of 650 patients across 12 countries completed early.
• First global Phase 3 win for Merck‑Kelun ADC partnership.

Pulse Analysis

Merck’s recent Phase 3 triumph with sac‑TMT underscores the growing strategic importance of antibody‑drug conjugates (ADCs) in oncology. ADCs combine the targeting precision of monoclonal antibodies with potent cytotoxic payloads, offering a way to treat tumours that have become resistant to conventional therapies. By partnering with Kelun‑Biotech, Merck leverages Kelun’s expertise in novel linker technologies and manufacturing capacity, accelerating development timelines and reducing costs—a model that other big pharma firms are increasingly emulating.

The trial’s results, a 30% reduction in progression‑free survival risk among roughly 650 patients, signal a competitive edge in a crowded market of targeted cancer treatments. For Merck, the data not only validates its investment in next‑generation biologics but also provides a critical hedge against the impending revenue decline from Keytruda’s patent expiration, projected to begin in 2028. Analysts estimate Keytruda generates over $15 billion annually; a successful ADC could recoup a meaningful portion of that gap, especially if the therapy secures regulatory approval in the United States and Europe.

Beyond Merck’s balance sheet, the success of sac‑TMT may accelerate broader industry adoption of Sino‑American collaborations. China’s biotech sector has matured, offering access to innovative platforms and large patient pools for trials. As regulatory pathways streamline and intellectual‑property frameworks improve, more Western pharma companies are likely to seek similar partnerships, reshaping the global drug development landscape and potentially delivering faster, more affordable cancer therapies to patients worldwide.